KTOV - Kitov Pharma secures new U.S. patent for anti-cancer drug candidate NT219

The USPTO has issued a Notice of Allowance to Kitov Pharma (KTOV) for a patent application entitled “Combinations of IRS/STAT3 Dual Modulators and Anti-Cancer Agents for Treating Cancer”.The patent which expires in 2036, covers the various combinations of NT219 with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO) for first-line treatment of EGFR-mutated non-small-cell lung carcinoma ((NSCLC)). Kitov recently initiated a Phase 1/2 trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab for the treatment of squamous cell carcinoma of the head and neck or colorectal adenocarcinoma. Top-line data is expected in H2 2021.Shares +4% premarket.

For further details see:

Kitov Pharma secures new U.S. patent for anti-cancer drug candidate, NT219